Gain Therapeutics (NASDAQ:GANX) Earns “Buy” Rating from HC Wainwright

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $8.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 298.01% from the company’s previous close.

A number of other equities research analysts have also recently issued reports on GANX. Chardan Capital reissued a “buy” rating and issued a $6.00 price target on shares of Gain Therapeutics in a research note on Friday, March 28th. Scotiabank started coverage on shares of Gain Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $8.20.

Gain Therapeutics Price Performance

Shares of NASDAQ GANX opened at $2.01 on Monday. The stock has a market capitalization of $59.15 million, a price-to-earnings ratio of -1.83 and a beta of 0.17. Gain Therapeutics has a 12 month low of $0.89 and a 12 month high of $3.19. The firm’s 50 day simple moving average is $1.94 and its 200-day simple moving average is $2.01. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.99 and a quick ratio of 2.99.

Gain Therapeutics (NASDAQ:GANX) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.16) EPS for the quarter, hitting analysts’ consensus estimates of ($0.16). Analysts expect that Gain Therapeutics will post -1 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dauntless Investment Group LLC purchased a new position in Gain Therapeutics in the 1st quarter valued at $240,000. Jones Financial Companies Lllp lifted its holdings in Gain Therapeutics by 83.6% in the 4th quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock valued at $212,000 after purchasing an additional 44,750 shares in the last quarter. Marshall Wace LLP purchased a new position in Gain Therapeutics in the 4th quarter valued at $198,000. Northern Trust Corp lifted its holdings in Gain Therapeutics by 88.2% in the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock valued at $183,000 after purchasing an additional 39,642 shares in the last quarter. Finally, Kovitz Investment Group Partners LLC purchased a new position in Gain Therapeutics in the 1st quarter valued at $91,000. Hedge funds and other institutional investors own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.